Molecular Pharmacology Stock Performance
| MLPH Stock | USD 0.0001 0.00 0.00% |
The company secures a Beta (Market Risk) of -0.17, which conveys not very significant fluctuations relative to the market. As returns on the market increase, returns on owning Molecular Pharmacology are expected to decrease at a much lower rate. During the bear market, Molecular Pharmacology is likely to outperform the market. At this point, Molecular Pharmacology has a negative expected return of -1.21%. Please make sure to verify Molecular Pharmacology's variance and kurtosis , to decide if Molecular Pharmacology performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Over the last 90 days Molecular Pharmacology has generated negative risk-adjusted returns adding no value to investors with long positions. Despite uncertain performance in the last few months, the Stock's basic indicators remain fairly strong which may send shares a bit higher in December 2024. The recent confusion may also be a sign of long-lasting up-swing for the firm traders. ...more
Molecular |
Molecular Pharmacology Relative Risk vs. Return Landscape
If you would invest 0.08 in Molecular Pharmacology on August 28, 2024 and sell it today you would lose (0.07) from holding Molecular Pharmacology or give up 87.5% of portfolio value over 90 days. Molecular Pharmacology is currently does not generate positive expected returns and assumes 11.3343% risk (volatility on return distribution) over the 90 days horizon. In different words, most equities are less risky than Molecular, and most traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Molecular Pharmacology Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Molecular Pharmacology's investment risk. Standard deviation is the most common way to measure market volatility of pink sheets, such as Molecular Pharmacology, and traders can use it to determine the average amount a Molecular Pharmacology's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.107
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | MLPH |
Estimated Market Risk
| 11.33 actual daily | 96 96% of assets are less volatile |
Expected Return
| -1.21 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.11 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Molecular Pharmacology is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Molecular Pharmacology by adding Molecular Pharmacology to a well-diversified portfolio.
Molecular Pharmacology Fundamentals Growth
Molecular Pink Sheet prices reflect investors' perceptions of the future prospects and financial health of Molecular Pharmacology, and Molecular Pharmacology fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Molecular Pink Sheet performance.
| Return On Asset | -5.69 | |||
| Current Valuation | 221.59 K | |||
| Shares Outstanding | 111.55 M | |||
| Price To Earning | (0.80) X | |||
| EBITDA | (98.11 K) | |||
| Cash And Equivalents | 1.52 K | |||
| Total Debt | 175.33 K | |||
| Book Value Per Share | (0.02) X | |||
| Cash Flow From Operations | (105.41 K) | |||
| Total Asset | 8.97 K | |||
| Current Asset | 9 K | |||
| Current Liabilities | 2.11 M | |||
About Molecular Pharmacology Performance
By evaluating Molecular Pharmacology's fundamental ratios, stakeholders can gain valuable insights into Molecular Pharmacology's financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Molecular Pharmacology has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Molecular Pharmacology has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements. Please also refer to our technical analysis and fundamental analysis pages.
Molecular Pharmacology Limited, a development stage company, develops and commercializes pain and inflammation management products primarily in Australia and the United States. Molecular Pharmacology Limited is a subsidiary of PharmaNet Group Limited. Molecular Pharmacology is traded on OTC Exchange in the United States.Things to note about Molecular Pharmacology performance evaluation
Checking the ongoing alerts about Molecular Pharmacology for important developments is a great way to find new opportunities for your next move. Pink Sheet alerts and notifications screener for Molecular Pharmacology help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Molecular Pharmacology generated a negative expected return over the last 90 days | |
| Molecular Pharmacology has high historical volatility and very poor performance | |
| Molecular Pharmacology has some characteristics of a very speculative penny stock | |
| Molecular Pharmacology has a very high chance of going through financial distress in the upcoming years | |
| Molecular Pharmacology currently holds 175.33 K in liabilities. Molecular Pharmacology has a current ratio of 0.27, indicating that it has a negative working capital and may not be able to pay financial obligations when due. Debt can assist Molecular Pharmacology until it has trouble settling it off, either with new capital or with free cash flow. So, Molecular Pharmacology's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Molecular Pharmacology sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Molecular to invest in growth at high rates of return. When we think about Molecular Pharmacology's use of debt, we should always consider it together with cash and equity. | |
| Net Loss for the year was (116.93 K) with profit before overhead, payroll, taxes, and interest of 0. | |
| Molecular Pharmacology currently holds about 1.52 K in cash with (105.41 K) of positive cash flow from operations. |
- Analyzing Molecular Pharmacology's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Molecular Pharmacology's stock is overvalued or undervalued compared to its peers.
- Examining Molecular Pharmacology's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Molecular Pharmacology's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Molecular Pharmacology's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Molecular Pharmacology's pink sheet. These opinions can provide insight into Molecular Pharmacology's potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for Molecular Pink Sheet analysis
When running Molecular Pharmacology's price analysis, check to measure Molecular Pharmacology's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Molecular Pharmacology is operating at the current time. Most of Molecular Pharmacology's value examination focuses on studying past and present price action to predict the probability of Molecular Pharmacology's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Molecular Pharmacology's price. Additionally, you may evaluate how the addition of Molecular Pharmacology to your portfolios can decrease your overall portfolio volatility.
| Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges | |
| Portfolio Dashboard Portfolio dashboard that provides centralized access to all your investments | |
| Financial Widgets Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets | |
| Headlines Timeline Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity | |
| Portfolio Comparator Compare the composition, asset allocations and performance of any two portfolios in your account | |
| Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities | |
| Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios | |
| Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk | |
| Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format |